Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, Atagi S, Kozuki T, Takeoka H, Chikamori K, Shinagawa N, Tanaka H, Horii E, Adrian S, Bruns R, Johne A, Paik PK, Sakai H.
Morise M, et al. Among authors: inoue t.
Cancer Sci. 2024 Apr;115(4):1296-1305. doi: 10.1111/cas.16107. Epub 2024 Feb 25.
Cancer Sci. 2024.
PMID: 38402853
Free PMC article.
Clinical Trial.